3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
23
Neoplasm Metastasis
9
Squamous Cell Carcinoma of Head and Neck
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Melanoma
2
Lymphangioma
2
Hyperglycemia
2
Head and Neck Squamous Cell Cancer
2
Vascular Malformations
1
Uveal Melanoma
1
Stomach Neoplasms
1
Solid Tumor
1
Skin Diseases, Vascular
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Oropharyngeal Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Meningioma
1
Lymphatic Abnormalities
1
Lymphangioma, Cystic
1
Hormone Receptor Positive Breast Carcinoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Exanthema
1
Interventions
mirdametinib
1
Therapeutics
1
Surgical Procedures, Operative
1
Sildenafil Citrate
1
Sclerotherapy
1
Risk Factors
1
Injections, Intralesional
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphatic Abnormalities
×
Alpelisib
×
Clear all
NCT05983159
2026-05-05
TARGET-VM
Murdoch Childrens Research Institute
Phase 2
Recruiting
50 enrolled